Brief: Neubase Therapeutics Estimates Cash And Cash Equivalents Are Sufficient To Fund Currently Planned Operating & Capex Into Q1 Of Cy2022
23/12/2020 21:19
Dec 23 (Reuters) - NeuBase Therapeutics Inc NBSE.O :
* NEUBASE THERAPEUTICS REPORTS BUSINESS UPDATE AND FINANCIAL
RESULTS FOR FISCAL YEAR 2020
* NEUBASE THERAPEUTICS - ESTIMATES CASH AND CASH EQUIVALENTS
ARE
SUFFICIENT TO FUND CURRENTLY PLANNED OPERATING & CAPEX INTO Q1
OF CY2022
Source text for Eikon: ID:nGNXc9NQsv
Further company coverage: NBSE.O
((reuters.briefs@thomsonreuters.com;))
Recent news on NeuBase Therapeutics
See all newsBrief: Neubase Therapeutics, On May 2, Was Notified By Nasdaq On Not Regained Compliance With Minimum Bid Price Requirement
Brief: Neubase Therapeutics Announces Receipt Of Notice From Nasdaq
U.S. STOCKS ON THE MOVE-TPG, R1 RCM, Zoom
U.S. STOCKS ON THE MOVE-Micron, Krystal Biotech, Pilgrim's Pride
U.S. STOCKS ON THE MOVE-Domino's Pizza, Voyager, Freshpet